Navigation Links
Neurocrine Biosciences Reports Third Quarter 2011 Results
Date:10/31/2011

aterially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's R & D pipeline and the Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's R & D pipeline include risk that elagolix, the company's lead clinical program, will fail to demonstrate that elagolix is safe and effective; risk that elagolix Phase III clinical trials will be delayed for regulatory or other reasons; and risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that the Company's urocortin 2 and VMAT2 clinical candidates will not proceed to later stage clinical trials; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended June 30, 2011. Ne
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
6. Neurocrine Biosciences Reports Third Quarter 2008 Results
7. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
9. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Announces Work Force Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... has announced the formation of a Medical Advisory Council ... (MiCK) assay for apoptosis , a new assay designed ... patients. DiaTech has introduced this technology for individual patient ... companies in validating new drugs that may be more ...
... 2011  Rhythm announced today that Lex Van der Ploeg, ... Dr. Van der Ploeg brings to Rhythm more than ... diseases, and other therapeutic areas. "Lex has ... metabolic pathways we are targeting with our ghrelin and ...
... mystery of prematurely dead cell phone and laptop batteries may ... energy grid according to Drexel researcher Dr. Yury Gogotsi. In ... Science , Gogotsi, who is the head of the ... of performance measurement for energy storage devices that are as ...
Cached Biology Technology:DiaTech Life Sciences Announces Medical Advisory Board 2DiaTech Life Sciences Announces Medical Advisory Board 3Rhythm Names Lex Van der Ploeg Chief Scientific Officer 2Drexel expert: Efficiency metrics for energy storage devices need standardization 2
(Date:10/25/2014)... , Oct. 22, 2014 This report covers ... relatively new space in heavy pursuit of research due ... to miRNAs compared to other RNA components. miRNA,s non-coding ... a novel candidate for use as a biomarker for ... miRNA-based microarrays and diagnostics for the advancement in therapeutic ...
(Date:10/22/2014)... , Oct. 20, 2014 The Nano-Bio ... States Air Force Research Laboratory (AFRL), has chosen a ... (AzCIM) at the University of Arizona College of Medicine ... funding.  The AzCIM project,s goal is to assess different ... collect different volumes of sweat under a variety of ...
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Researchers find why depression and aging linked to increased disease risk 2
... from an observational study by researchers at the University ... 65 and 80 years of age who received treatment ... than men who did not receive treatment. The study ... the Journal of the American Medical Association. , Thanks ...
... possible new cancer drug suggests that it may prove ... chemotherapeutic drugs. , Dr David Huang, Dr Andrew Roberts, ... research divisions have been assessing the potential of a ... company, Abbott. , Under normal circumstances, human ...
... to light is missing in humans, researchers have discovered. , ... amphibians have two versions of this photoreceptor, mammals, including humans, ... Public Library of Science journal PLoS Biology ?reveal how our ... other vertebrates and fits with the suggestion that early mammals ...
Cached Biology News:Older men treated for early prostate cancer live longer than those who are not 2Hope for a more effective and less toxic cancer drug 2Does missing gene point to nocturnal existence for early mammals? 2
Reacts with the 80 kDa fragment of the M-chain of human merosin....
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
... polyclonal to ZFP91 ( Abpromise ... Antigen: Synthetic peptide derived ... human ZFP91. (Note: the amino ... Entrez Gene ID: ...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: